Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 28, 2023
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adultsClaudia Tandler, Jonas S Heitmann, Tanja M Michel, et al.
Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.
Clinical Therapeutics|February 7, 2026
Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19Maddalena Marconato, Christopher Hackenbruch, Simon Jäger, et al.
Nature Communications|November 18, 2023
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
British Journal of Cancer|February 24, 2023
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccinationLena Mühlenbruch, Tsima Abou-Kors, Marissa L Dubbelaar, et al.
Blood|December 12, 2018
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapyTatjana Bilich, Annika Nelde, Leon Bichmann, et al.
Scientific Reports|July 18, 2025
Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed familiesAlex Dulovic, Armin Rabsteyn, Jonathan Remppis, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2017
The immunopeptidomic landscape of ovarian carcinomasHeiko Schuster, Janet K Peper, Hans-Christian Bösmüller, et al.
Nature|November 23, 2021
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Pageof 10